Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
RESEARCH TOOLSreports
PACB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.16 - $6.09
Previous CloseN/A
Volume8.28M
Average Volume (3M)13.25M
Market Cap
$512.12M
Enterprise Value$912.87M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.14
Next Earnings
May 08, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding273,863,560
10 Day Avg. Volume17,999,730
30 Day Avg. Volume13,245,305
Standard Deviation0.27
R-Squared0.14
Alpha-0.00578
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.96
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.30
Enterprise Value/Ebitda-2.85
Forecast
1Y Price Target
$2.19Price Target Upside23.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe Vega system rollout is progressing well, with plans to ramp up production and reduce costs, which should boost gross margins.
Product DevelopmentThe launch of Vega should unlock a new portion of the market for PacBio, and recent advancements to Revio should help the product rebound.
Bears Say
Macroeconomic FactorsMacroeconomic pressures persisted and sales cycles continue to be elongated.
---
Ownership Overview
2.45% Insiders
13.19% Mutual Funds
0.27% Other Institutional Investors
60.56% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $1.16 and its highest was $6.09 in the past 12 months.
What is Pacific Biosciences’s market cap?
Pacific Biosciences’s market cap is $512.12M.
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is May 08, 2025 which is in 77 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Feb 13, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.2.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -0.19.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 273,863,560 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went up 25%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Currently, no hedge funds are holding shares in PACB
---
Pacific Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.19 (23.73% Upside)
$2.19 (23.73% Upside)
Blogger Sentiment
Bearish
PACB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $720.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.16%
12-Months-Change
Fundamentals
Return on Equity
-51.05%
Trailing 12-Months
Asset Growth
-27.74%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
---
PACB Company Deck
---
PACB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
PacBio demonstrated strong growth in genomic data output and consumable revenue, along with successful product launches and cost reductions. However, significant challenges remain, including a substantial decline in instrument revenue, macroeconomic and funding uncertainties, and extended cash flow breakeven timeline due to recent challenges.Read More>---
PACB Stock 12 Month Forecast
Average Price Target
$2.19
▲(23.73% Upside)
Technical Analysis
Best Analysts Covering PACB
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
+10.94%
reiterated a buy rating 8 days ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +10.94% per trade.
---